



Oifig an Stiúirthóra Náisiúnta  
Géaroibríochtaí

Aonad 4A, Áras Dargan, An Ceantar Theas,  
An Bóthar Mileata, Cill Mhaighneann, Baile  
Átha Cliath 8, D08 NN9V

Office of the National Director  
Acute Operations

Unit 4a, the Dargan Building, Heuston  
South Quarter, Military Road,  
Kilmainham, Dublin 8, D08 NN9V

www.hse.ie  
@hselive

t 01 795 9972  
e acutehospitals@hse.ie

Deputy Pádraig O'Sullivan  
Dáil Éireann  
Leinster House  
Dublin 2

12<sup>th</sup> July 2023

**PQ 28656/23 To ask the Minister for Health to outline the expenditure levels of new medicines and new uses of existing medicines in 2022 on an in-year basis under acute spending; and if he will make a statement on the matter.**

Dear Deputy O Sullivan

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary question, which you submitted to the Minister for Health for response.

In 2022, the HSE approved in excess of 60 new medicine / license extensions for existing medicines across the health system, the majority of which are on the Community Drugs Schemes.

From the dispensing data available to Acute Operations;

- The acute spending on the six new Hospital Approvals medicines in 2022 amounted to €497K (excl. Vat).
- Two new haematology-oncology medicines were approved in 2022. The HSE spend on these medicines is not available from Acute Operations.
- Numerous license extensions for existing hospital and haematology oncology medicines were approved in 2022. It is not possible to isolate the costs associated with the license extensions of medicines.

I trust this is of assistance to you.

Yours sincerely,

**Nessa Lynch**  
**General Manager**  
**Acute Operations**